Mutations in apoA-I may associate with low levels of plasma HDL cholesterol and apoA-I due to defective LCAT activation or to amyloidosis, or to amyloidosis with only minor or no effects on apoA-I and HDL cholesterol levels [5]–[11]. Here, LCAT is linked to amyloidosis.